EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing Thrombolysis Safety in Post-Acute Ischemic Stroke with Tissue Plasminogen Activator-Associated Microparticles

Raffaele Spanò iD, Corinne Portioli, Tijana Geroski, Alessia Felici, Anna Lisa Palange, Peter James Gawne iD, Stefania Mamberti iD, Greta Avancini iD, Roberto Palomba iD, Thomas Bonnard, Thomas Lee Moore, Massimo Del Sette und 3 weitere

ACS Nano · 2025

DOI: 10.1021/acsnano.5c01499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2025. Verfasst von Raffaele Spanò und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Genoa 16163, Italy. Hauptthemen laut MEDLINE: Tissue Plasminogen Activator, Ischemic Stroke, Thrombolytic Therapy, Fibrinolytic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant tissue-type plasminogen activator (tPA) is the only approved thrombolytic drug for acute ischemic stroke, a condition associated with severe disabilities and high mortality. However, when the blood-brain barrier (BBB) is damaged, tPA can exacerbate cerebral injury and increase the risk of hemorrhagic transformation, limiting its use to a small subset of patients. To address this challenge and minimize extravascular accumulation, we combined tPA with micrometer-sized particles (DPN). We then tested their safety and neuroprotective effects. After a 1 h transient occlusion of the middle cerebral artery, free tPA, tPA-DPN, or saline was administered to assess mice survival, neurological behavior, and infarcted area extent. Free-tPA exacerbated brain damage, resulting in a modest 10% survival rate at 24 h post intervention. Conversely, tPA-DPN displayed a far better prognosis, with a 75% survival rate comparable to that of saline. No statistical differences were documented between tPA-DPN and saline for the Activity Score and the Neurological Severity Score. tPA-DPN did not increase lesion volume or BBB permeability, unlike free-tPA, which led to an over 2-fold enlarged lesion volume and 50% higher BBB permeability. The safety profile of tPA-DPN is attributed to the robust conjugation of tPA onto DPN and the lack of DPN extravasation, resulting in negligible cerebrovascular damage of free tPA and glial and neuron impairment. The vascular confinement of tPA linked to microscopic particles reduces drug side effects and represents a valuable strategy for safe and effective tPA delivery, even in the postacute stroke phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tissue Plasminogen ActivatorIschemic StrokeThrombolytic TherapyFibrinolytic AgentsAnimalsMiceBlood-Brain BarrierMaleMice, Inbred C57BLParticle Size

Stichwörter der Autor:innen

blood–brain barrierglial cellsnanomedicineneuroprotectionthrombolytics

Substanzen

Tissue Plasminogen ActivatorFibrinolytic Agents

Autor:innen und Institutionen

  • Laboratory of Nanotechnology for Precision Medicine, Fondazione Istituto Italiano di Tecnologia, Genoa 16163, Italy.
  • Faculty of Engineering, University of Kragujevac, Kragujevac 34000, Serbia.
  • Institute Blood and Brain @ Caen-Normandie (BB@C), Physiopathology and Imaging of Neurological Disorders (PhIND), Normandie University, UNICAEN, INSERM, GIP Cyceron, Caen 14000, France.
  • Neurology Unit and Stroke Unit, IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy.
  • Clinical Research Department, CHU de Caen Normandy, Caen 14000, France.
  • Division of Oncology, Department of Medicine and Department of Pathology, Stanford University School of Medicine, Stanford California 94305, United States.

ORCID-Profile: Raffaele Spanò, Peter James Gawne, Stefania Mamberti, Greta Avancini, Roberto Palomba, Paolo Decuzzi

Förderung

  • European Research Council

Zitieren

APA

Spanò, R., Portioli, C., Geroski, T., Felici, A., Palange, A. L., Gawne, P. J., Mamberti, S., Avancini, G., Palomba, R., Bonnard, T., Moore, T. L., Del Sette, M., Filipovic, N., Vivien, D., & Decuzzi, P. (2025). Enhancing Thrombolysis Safety in Post-Acute Ischemic Stroke with Tissue Plasminogen Activator-Associated Microparticles. ACS Nano. https://doi.org/10.1021/acsnano.5c01499

Vancouver

Spanò R, Portioli C, Geroski T, Felici A, Palange AL, Gawne PJ, et al. Enhancing Thrombolysis Safety in Post-Acute Ischemic Stroke with Tissue Plasminogen Activator-Associated Microparticles. ACS Nano. 2025. doi:10.1021/acsnano.5c01499

BibTeX
@article{Span2025,
  author = {Spanò, Raffaele and Portioli, Corinne and Geroski, Tijana and Felici, Alessia and Palange, Anna Lisa and Gawne, Peter James and Mamberti, Stefania and Avancini, Greta and Palomba, Roberto and Bonnard, Thomas and Moore, Thomas Lee and Del Sette, Massimo and Filipovic, Nenad and Vivien, Denis and Decuzzi, Paolo},
  title = {Enhancing Thrombolysis Safety in Post-Acute Ischemic Stroke with Tissue Plasminogen Activator-Associated Microparticles},
  journal = {ACS Nano},
  year = {2025},
  doi = {10.1021/acsnano.5c01499}
}
Kostenlos starten →